MACULAR DEGENERATION (AGE-RELATED)
REFERENCES
1. Gass JD. Stereoscopic Atlas of Macular Disease: Diagnosis and Treatment
4th ed. St. Louis: Mosby; 1997: 70-2.
2. Klein R, Klein BE et al. The five-year incidence and progression of age-related
maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997 Jan;104(1):7-21.
3. Leibowitz HM, Krueger DE et al. The Framingham eye study monograph: an
ophthalmological and epidemiological study of cataract, glaucoma, diabetic
retinopathy, macular degeneration, and visual acuity in a general population
of 2631 adults, 1973-1975. Surv Ophthalmol. 1980;24:335-610.
4. Schachat AP, Hyman L, et al. Features of age-related macular degeneration
in a black population. The Barbados Eye Study Group. Arch Ophthalmol. 1995;113:728-35.
5. Bird AC, Bressler NM et al. An international classification and grading
system for age-related maculopathy and age-related macular degeneration. The
International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367-74.
6. Anon. American Academy of Ophthalmology Website 2004. www.aao.org/public/pi/eye_health/safety/ecm_care.html.
7. Yanoff M, Duker JS. Ophthalmology 2nd ed. St. Louis: Mosby; 2004: 925-33.
8. Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician
1999;60:99-108.
9. Vrabec T, Tantri A et al. Autosomal dominant Stargardt-like macular dystrophy:
identification of a new family with a mutation in the ELOVL4 gene. Am J Ophthalmol.
2003;136(3):542-5.
10. Michaelides M, Hunt D et al. The genetics of inherited macular dystrophies.
J Med Genet. 2003;40(9):641-50.
11. Meyers SM, Grene T et al. A twin study of age-related macular degeneration.
Am J Ophthalmol. 1995; 120: 757-66.
12. Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol.
1987;31:291-306.
13. Kaufman PL. Alm A. Adler’s physiology of the eye-clinical application.
Mosby: New York; 2003. 319-47.
14. Friedman E. The role of the atherosclerotic process in the pathogenesis
of age-related macular degeneration. Am J Ophthalmol. 2000;130:658-63.
15. Bressler NM, Bressler SB et al. The grading and prevalence of ge-related
macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol. 1989;107:847-52.
16. Seddon, JM, Willett WC et al. A prospective study of cigarette smoking
and age-related macular degeneration in women. JAMA 1996 Oct 9; 276(14): 1141-6.
17. Giblin FJ. Glutathione: a vital lens antioxidant. J Ocul Pharmacol Ther.
2000 Apr;16(2):121-35.
18. Brubaker RF, Bourne WM et al. Ascorbic acid content of human corneal
epithelium. Invest Ophthalmol Vis Sci 2000 Jun;41(7):1681-3.
19. Zarbin M. Current concepts in the pathogenesis of age-related macular
degeneration. Arch Ophthalmol 2004;122(4):598-614.
20. Nilsson S. Sundelin S et al. Aging of cultured retinal pigment epithelial
cells: oxidative reactions,lipofuscin formation and blue light damage. Doc
Ophthalmol. 2003 Jan;106(1):13-6.
21. Miyazaki M. Nakamura H et al. Risk factors for age-related maculopathy
in a Japanese population: the Hisayama study. Brit J Ophthalmol. 2003;87(4):469-72.
22. De la Marnierre E, Guigon B et al. Phototoxic drugs and age-related maculopathy.
J Fr Ophthalmol. 2003 26(6):596-601.
23. Semba R. Dagnelle G. Are lutein and zeaxanthin conditionally essential
nutrients for eye health? Med Hypotheses 2003; 61(4):465-72.
24. Richer S, Stiles W, et al. Double-masked, placebo-controlled, randomized
trial of lutein and antioxidant supplementation in the intervention of atrophic
age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant
Supplementation Trial). Optometry. 2004 Apr;75(4):216-30.
25. Seddon JM, Rosner B et al. Dietary fat and risk for advanced age-related
macular degeneration. Arch. Ophthalmol. 2001 Aug;119(8):1191-9.
26. Kolb H, Fernandez E, et al. Anatomy and physiology of the retina. www.webvision.med.utah.edu.
Accessed 9/2004.
27. Fatt I, Weissman B. Physiology of the Eye: An Introduction to the Vegetative
Functions. Butterworth-Heinemann: Boston; 1992: 1-14, 213-17.
28. Davson H. Physiology of the Eye. Pergamon Press: New York. 1990: 230-54.
29. Stein. Internal Medicine. Mosby: New York. 1998: 2301-2.
30. Reber F, Kasper M, et al. Alteration of the intracellular pH and apoptosis
induction in a retinal cell line by the AGE-inducing agent glyoxal. Graefes
Arch Clin Exp Ophthalmol. 2002 Dec;240(12):1022-32.
31. Laedwig M. Kraus H. et al. Cone dysfunction in patients with late-onset
cone dystrophy and age-related macular degeneration. Arch Ophthalmol. 2003;121(11):1557-61.
32. Shukla M. Hydergine-a new promise in neuro-retinal disorders. Afro-Asian
J. Ophthalmol. 1989;8(1):28-30.
33. Kaven C, Spraul CW et al. Thalidomide and prednisolone inhibit growth
factor-induced human retinal pigment epithelium cell proliferation in vitro.
Ophthalmologica 2001 Jul-Aug;215(4):284-9.
34. Anon. Laser photocoagulation for juxtafoveal choroidal neovascularization.
Five-year results from randomized clinical trials. Macular Photocoagulation
Study Group. Arch Ophthalmol. 1994;112:500-9.
35. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem
Photobiol. 1992;55:145-157.
36. Bressler NM, Bressler SB Photodynamic therapy with verteporfin (Visudyne):
impact on ophthalmology and visual sciences. Invest. Ophthalmol. Vis. Sci.
2000 Mar; 41(3): 624-8.
37. Bressler NM, Vertporfin therapy of subfoveal choroidal neovasuclarization
in age-related mauclar degeneration: two-year results of a randmoized clinical
trial including lesions with occult with no classic choroidal neovascularization.
Verteporfin in Photodynamic Therapy report 2. Am J ophthalmol. 2002;133:168-9.
38. Beatty S, Koh H, et al. The role of oxidative stress in the pathogenesis
of age-related macular degeneration. Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34.
39. Beatty S, Murray IJ et al. Macular pigment and risk for age-related macular
degeneration in subjects from a Northern European population. Invest. Ophthalmol
Vis Sci. 2001 Feb; 42(2): 439-46.
40. Bone RA, Landrum JT, et al. Lutein and zeaxanthin in the eyes, serum
and diet of human subjects. Exp Eye Res. 2000 Sep; 71(3): 239-45.
41. Bone RA, Landrum JT et al. Macular pigment in donor eyes with and without
AMD: a case-control study. Invest Ophthalmol Vis Sci. 2001 Jan; 42(1): 235-40.
42. Rapp LM, Maple SS et al. Lutein and zeaxanthin concentrations in rod
outer segment membranes from perifoveal and peripheral human retina. Invest
Ophthalmol Vis Sci. 2000 Apr;41(5):1200-9.
43. Landrum JT, Bone RA Lutein, zeaxanthin, and the macular pigment. Arch
Biochem Biophys 2001 Jan 1;385(1):28-40.
44. Lutty G, Grunwald J et al. Changes in choriocapillaris and retinal pigment
epithelium in age-related macular degeneration. Mol Vis. 1999 Nov 3;5:35.
45. Smith W, Mitchell P et al. Dietary fat and fish intake and age-related
maculopathy. Arch Ophthalmol. 2000 Mar;118(3):401-4.
46. Colantuoni A, Bertuglia S et al. Effects of vaccinium myrtillus anthocyanosides
on arterial vasomotion. Arzneimittelforschung. 1991 Sep;41(9):905-9.
47. Bravetti G. Preventive medical treatment of senile cataract with Vitamin
E and anthocyanosides: Clinical Evaluation. Ann Ottalmol Clin Ocul. 1989;115:109.
48. Piovella, C. Effects of ginkgo-biloba on the micro-vessels of bulbar
conjunctiva. Minerva Med. 1973 Nov 7;64(79 Suppl.):4179-86 (in Italian).
49. Blumenthal M, Busse WR et al. The Complete German Commission E Monographs:
Therapeutic Guide to Herbal Medicines. American Botanical Council, 1998.
50. Anon. Oligomeric proanthocyanidins (OPC). Monograph. Altern Med Rev.
2003;8(4):442-50.
51. Specht S, Organisciak DT et al. Continuing damage to rat retinal DNA
during darkness following light exposure. Photochem Photobiol. 2000 May;71(5):559-66.
52. Lopez B, Ubels JL. Artificial tear composition and promotion of recovery
of the damaged corneal epithelium. Cornea. 1993 Mar;12(2):115-20.
53. Hayes KC, Carey RE et al. Retinal degeneration associated with taurine
deficiency in the cat. Science 1975 Jun 30;188(4191):949-51.
54. Packer L Tritschler HJ et al. Neuroprotection by the metabolic antioxidant
alpha-lipoic acid. Free Radic Biol Med. 1997;22(1-2):359-78.
55. Head KA. Natural therapies for ocular disorders, part 1: diseases of
the retina. Altern Med Rev. 1999;4(5):342-59.
56. Head KA. Natural therapies for ocular disorders, part 2: cataracts and
glaucoma.
Altern Med Rev. 2001 Apr;6(2):141-66.
57. Blasi MA, Bovina C, et al. Does coenzyme Q10 play a role in opposing oxidative
stress in patients with age-related macular degeneration? Ophthalmologica.
2001 Jan-Feb;215(1):51-4.
58. Feher J, Papale A et al. Mitotropic compounds for the treatment of age-related
macular degeneration. The metabolic approach and a pilot study. Ophthalmologica.
2003 Sep-Oct;217(5):351-7.
59. Lenaz G, D'Aurelio M et al. Mitochondrial bioenergetics in aging. Biochim
Biophys Acta. 2000 Aug 15;1459(2-3):397-404.
60. Anon., AREDS reports. Arch Ophthalmol. 2001.
61. Gaziano JM, Johnson EJ et al. Discrimination in absorption or transport
of beta-carotene isomers after oral supplementation with either all-trans-
or 9-cis-beta-carotene. Am J Clin Nutr. 1995;61:1248-52.
|